Tag: pre-IPO

In a preprint paper published on MedRxiv, a team of scientists at CureLab Oncology and their international collaborators have demonstrated a clear clinical benefit of a new biological agent against the deadliest form of ovarian cancer. The results were derived from a clinical study that evaluated the safety and…

Why join Freenome? Freenome is a high-growth biotech company developing tests to detect cancer using a standard blood draw. To do this, Freenome uses a multiomics platform that combines tumor and non-tumor signals with machine learning to find cancer in its earliest, most-treatable stages. Cancer is relentless. This is why…

Why join Freenome?Freenome is a high-growth biotech company developing tests to detect cancer using a standard blood draw. To do this, Freenome uses a multiomics platform that combines tumor and non-tumor signals with machine learning to find cancer in its earliest, most-treatable stages.Cancer is relentless. This is why Freenome is…

With biotech funding trends always evolving, HSBC Innovation Banking’s inaugural Venture Healthcare Report lays out the trends seen in the first half (1H) of 2023, where valuations underwent a necessary reset, and venture capitalists emerged from their cautious stance, eventually embarking on a fresh wave of investments. However, an overall…

Joining this employer offers a unique opportunity to be part of a high-growth biotech company revolutionizing cancer detection through advanced technology and machine learning. By joining our team, you will have the chance to make a significant impact on patients’ lives by contributing to the development of tests that can…

Why join Freenome? Freenome is a high-growth biotech company developing tests to detect cancer using a standard blood draw. To do this, Freenome uses a multiomics platform that combines tumor and non-tumor signals with machine learning to find cancer in its earliest, most-treatable stages.  Cancer is relentless. This is why…

Why join Freenome? Freenome is a high-growth biotech company developing tests to detect cancer using a standard blood draw. To do this, Freenome uses a multiomics platform that combines tumor and non-tumor signals with machine learning to find cancer in its earliest, most-treatable stages.  Cancer is relentless. This is why…

Excision BioTherapeutics (“Excision”) is a pre-IPO biotechnology, clinical stage company developing novel CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients by eliminating viral genomes from infected individuals. Excision has an ongoing phase 1/2 Trial of EBT-101 CRISPR-based therapeutic for treatment of HIV patients….

​​​I recently noted that interactive investor, whether or not it goes ahead with a stock market flotation, can already be held via the Unicorn AIM VCT (UAV)​​​​​​. But it’s worth adding that other companies tipped for “hot” initial public offerings (IPO) are also available via trusts – some of which…